Physician profile
Mark H Stephen
NPI 1356555916
$3,429.95
in general payments reported to CMS, 2019-2025
40 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $235 · 2021: $411 · 2022: $520 · 2023: $773 · 2024: $840 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $425.42 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $294.31 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $275.49 | 2020-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $256.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $180.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.75 | 2019-2024 | Breztri, Lokelma, Airsupra |
| Lilly USA, LLC | $147.33 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $125.08 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $119.37 | 2021-2025 | Eohilia |
| Medtronic, INC. | $118.13 | 2021 | |
| Exact Sciences Corporation | $93.81 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $89.16 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $84.77 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $82.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $78.69 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.